Chordate Medical Holding
0.60 SEK
-2.60 %
Less than 1K followers
CMH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-2.60 %
-86.67 %
-90.71 %
-90.91 %
-92.39 %
-95.56 %
-99.74 %
-99.61 %
-99.96 %
Chordate Medical Holding is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulatory and drug-free treatment technique for chronic migraine and chronic rhinitis. The treatment has proven efficacy according to a clinical study and is marketed in selected markets in the EU and the Middle East. The company is headquartered in Kista.
Read moreMarket cap
1.62M SEK
Turnover
2.08K SEK
Revenue
660K
EBIT %
-4,159.09 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5/12
2025
Interim report Q3'25
8/12
2025
Extraordinary general meeting '25
27/2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
Notice to the Extraordinary General Meeting in Chordate Medical Holding AB (publ)
Styrelsen för Chordate föreslår att bolagsstämman fattar beslut om frivillig likvidation och avnotering
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools